Giant Biogene Holding Co (HKSE:02367) EBIT : HK$1,909 Mil (TTM As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Giant Biogene Holding Co EBIT?

Giant Biogene Holding Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$1,060 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1,909 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Giant Biogene Holding Co's annualized ROC % for the quarter that ended in Dec. 2023 was 184.08%. Giant Biogene Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 270.05%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Giant Biogene Holding Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.25%.

Giant Biogene Holding Co EBIT Historical Data

The historical data trend for Giant Biogene Holding Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Giant Biogene Holding Co EBIT Chart

Giant Biogene Holding Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

754.07

961.87

1,191.31

1,315.23

1,908.86

Giant Biogene Holding Co Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial			-	601.45	742.26	848.38	1,060.49

Competitive Comparison of Giant Biogene Holding Co's EBIT

For the Household & Personal Products subindustry, Giant Biogene Holding Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Giant Biogene Holding Co's EV-to-EBIT Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Giant Biogene Holding Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Giant Biogene Holding Co's EV-to-EBIT falls into.

Giant Biogene Holding Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$1,909 Mil.

Giant Biogene Holding Co (HKSE:02367) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Giant Biogene Holding Co's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	2062.43 * ( 1 - 19.32% )	/	( (848.877	+	959.043)	/ 2 )
=	1663.968524	/	903.96
=	184.08 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4241.702	-	350.956	-	( 3041.869	-	max(0, 367.771	-	3428.88	+	3041.869	))
=	848.877

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5439.448	-	537.915	-	( 4133.144	-	max(0, 580.372	-	4522.862	+	4133.144	))
=	959.043

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Giant Biogene Holding Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2120.97	/	( ( (663.48 + max(-63.249, 0))	+	(907.325 + max(-270.7, 0)) )	/	2 )
=	2120.97	/	( ( 663.48	+	907.325 )	/	2 )
=	2120.97	/	785.4025
=	270.05 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(99.554	+	203.98	+	0.0010000000002037)	-	(350.956	+	0	+	15.828)
=	-63.249

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(88.725	+	219.237	+	0)	-	(537.915	+	0	+	40.747)
=	-270.7

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Giant Biogene Holding Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	1908.865	/	44933.404
	=	4.25 %

Giant Biogene Holding Co EBIT Related Terms

Thank you for viewing the detailed overview of Giant Biogene Holding Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Giant Biogene Holding Co (HKSE:02367) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Giant Biogene Holding Co Ltd (HKSE:02367) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1855, Shanglin Yuan 7th Road, Chang’an District, Shaanxi Province, Xi’an, CHN

Website

http://www.xajuzi.com

Giant Biogene Holding Co Ltd design, develop and manufacture professional skin treatment products with recombinant collagen as the key bioactive ingredient. The company also develops and manufactures rare ginsenosides technology-based functional foods. The company utilizes proprietary synthetic biology technology to develop and manufacture multiple types of recombinant collagen and rare ginsenosides in-house. Bioactive ingredients offer a wealth of beauty and health properties such as skin repair, anti-aging, whitening, moisturizing and immunity improvement with a broad range of applications in the beauty and health sectors.

Executives

Refulgence Holding Limited	2201 Interest of corporation controlled by you
Juzi Holding Co., Ltd	2101 Beneficial owner
Fan Daidi	2201 Interest of corporation controlled by you
Yan Jianya	2202 Interest of your spouse
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Yan Jianya	2101 Beneficial owner
Fan Daidi
Trident Trust Company (b.v.i.) Limited	2301 Trustee

Giant Biogene Holding Co (HKSE:02367) Headlines

No Headlines